Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
News|Articles|September 18, 2023

Worldwide Clinical Trials’ Clinical Pharmacology Unit Earns Accreditation from the College of American Pathologists

Worldwide Clinical Trials has announced its Early Phase Clinical Pharmacology Unit (CPU) has been awarded accreditation from the College of American Pathologists (CAP). To achieve accreditation, the clinic passed an evaluation process that involved an in-depth inspection of its clinical laboratory facilities, equipment, processes, quality control measures, and personnel qualifications—conducted onsite by CAP inspectors.

“The College of American Pathologists is known for the highest standards in laboratory quality,” said Mike Mencer, executive vice president and general manager, Early Phase in a press release. “The CAP Laboratory Accreditation Program provides a clear roadmap for running a high-quality clinical laboratory, with checklists updated annually to ensure we stay current with rapidly evolving advances in medicine, technology, and regulatory compliance as we partner with our customers to develop new medications and treatments. As the latest in our series of investments in facilities, capabilities, and certifications, this accreditation upholds our culture of quality and our commitment to provide customized services to every clinical research program we launch, while adhering to stringent regulatory requirements.”

Operating since 2005 and located in San Antonio, Texas, Worldwide’s CPU is a 200-bed, fit-for-purpose facility. Within this unit, studies are conducted in healthy volunteers, patients, and specialty populations. The CPU is located one hour from Worldwide’s Bioanalytical Center of Excellence, offering an approach that benefits customers through vendor management, consistent standards, technical expertise, and overall efficiencies such as sample transfer and processing.

Worldwide opened the Bioanalytical Center of Excellence in June 2022 in Austin, Texas, to support its Early Phase development and expansion. The 57,000 square foot facility offers about 20 percent more usable space than the previous lab, and is outfitted with modern infrastructure, improved air control, and efficient lab space to flexibly support current and future early phase research demands while enabling optimized workflows to ensure critical customer timelines are met. The expansion also included the addition of large molecule capabilities and services, led by Dr. Tom Zhang, with a 15,000 square foot large molecule lab within the Bioanalytical Center of Excellence.

Reference

Worldwide Clinical Trials’ Clinical Pharmacology Unit Earns Accreditation from the College of American Pathologists. (2023, September 14). Business Wire.


Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.